The point of Rick Shea’s comment is that a non-interchangeable generic Lovenox from Teva (or anyone else) does not count as a second generic Lovenox in the marketplace in the contractual formula that determines how much MNTA gets paid by NVS. In other words, if the FDA ends up approving an interchangeable generic from NVS/MNTA and a non-interchangeable generic from Teva, the economics for MNTA are just as good as the case where NVS/MNTA gets approved and Teva gets rejected.
News 
Market Data 
Discover 
